HC Wainwright Estimates Agenus’ Q4 Earnings (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN) – Investment analysts at HC Wainwright boosted their Q4 2024 EPS estimates for Agenus in a research note issued to investors on Thursday, December 5th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will earn ($2.62) per share for the quarter, up from their prior estimate of ($2.88). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.93) per share. HC Wainwright also issued estimates for Agenus’ Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($6.85) EPS, FY2026 earnings at ($6.04) EPS, FY2027 earnings at ($6.45) EPS and FY2028 earnings at ($6.70) EPS.

Several other equities analysts also recently issued reports on AGEN. B. Riley decreased their price objective on shares of Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $10.00.

Agenus Price Performance

Shares of AGEN stock opened at $3.58 on Monday. Agenus has a 1-year low of $2.50 and a 1-year high of $19.69. The company has a market cap of $83.98 million, a price-to-earnings ratio of -0.32 and a beta of 1.24. The stock has a 50 day simple moving average of $3.98 and a 200-day simple moving average of $7.78.

Hedge Funds Weigh In On Agenus

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in shares of Agenus by 13.7% during the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after buying an additional 4,134,232 shares during the last quarter. Geode Capital Management LLC increased its stake in Agenus by 7.1% during the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after acquiring an additional 32,016 shares during the last quarter. State Street Corp raised its position in Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after purchasing an additional 9,731 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Agenus by 52.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 123,058 shares during the last quarter. Finally, Walleye Capital LLC purchased a new position in shares of Agenus during the 3rd quarter worth $1,003,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.